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Extraosseous osteosarcoma (EOO) is a malignant mesenchymal neoplasm that is located in the soft tissues without direct
attachment to the skeletal system and that produces osteoid, bone, or chondroid material. EOO is an extremely rare disease,
accounting for only 1% of soft tissue sarcomas, and typically presents in either an extremity or the retroperitoneum. This paper
presents the case of a 45-year-old Caucasian male with extraosseous osteosarcoma of the esophagus.
1.CaseReport
A 45-year-old Caucasian man ﬁrst noticed a change in his
normal state of health with some hoarseness in his voice.
This hoarseness persisted for just over a week with no
other associated symptoms. As the hoarseness resolved, the
patient began to experience signiﬁcant dysphagia to both
hard and soft foods. Associated symptoms included nausea
and regurgitation, but no emesis. He had also developed a
new persistent cough, which was productive of clear mucus
and sometimes scant hemoptysis. The patient reported
fatigue, mild dyspnea on exertion, and a 10–15 pound
weight loss over the ensuing 6–8 weeks. The patient was a
lifetime nonsmoker and up until 3 years earlier had drank
approximately 24 twelve ounce beers per week for several
years. The family history was reviewed and was negative for
any malignancy or familial syndromes with a predisposition
for malignancy. The patient was seen by his primary care
physician who ordered a chest CT scan, revealing multiple
small polypoid lesions, all measuring less than 5mm, along
the wall of his distal trachea and proximal left main
bronchus. There were also multiple enlarged calciﬁed lymph
nodes in the superior mediastinum. The work up continued
with an esophagogastroduodenoscopy, which showed an
ulceratedlesionextendingfrom20to30cmfromtheincisors
(Figure 1). Endoscopic ultrasound (EUS) was limited but
did conﬁrm a large mass in the right posterior margin
of the upper esophagus. Biopsies were taken and showed
mitotically active spindle cells and focal areas containing
eosinophilic stromal hyaline-like material—osteoid. The
tumor cells were noted to be vimentin positive, but negative
for cytokeratin, desmin, CD117, Melanin, CD45, CD3 and
CD20—further supporting the diagnosis of EOO (Figure 2).
The patient underwent bronchoscopy showing multiple
endobronchialmasses;biopsiesweretakenandagainshowed
pleomorphic spindle cells. The patient also had a palpable
lymph node in his right supraclavicular region; this was
biopsied, and pathology results were consistent with EOO. A
PET/CTrevealedanextensive,calciﬁed,lobulatedesophageal
mass (Figure 3) with intense FDG avidity extending from T1
to T8, approximately 16cm in length. In addition, he had
bilateral FDG-avid level VI cervical lymph nodes, FDG-avid
lymphadenopathy in the mediastinum, multiple bilateral
pulmonary nodules, and calciﬁed FDG-avid gastrohepatic
lymph nodes.
The patient underwent placement of an esophageal
stent, which helped relieve his dysphagia. Medical oncology
was consulted to determine the role of systemic therapy.
The patient was seen, evaluated, and scheduled to receive
4 cycles of doxorubicin and cisplatin. Given the advanced2 Sarcoma
Figure 1: The proximal portion of the nodular tumor as seen on
endoscopy of the esophagus. At time of this endoscopy, there was
a severe stricture secondary to the tumor and a 6mm scope was
u n a b l et ob ep a s s e db e y o n di t .
disease present in the patient, chemotherapy consisting of
doxorubicin and cisplatin was decided to be the best course
of treatment. The patient went to the OR for placement of
a port with repeat esophagoscopy. The tumor had increased
considerably from the previous endoscopy and the patient
was not able to be extubated due to signiﬁcant local
invasion of the tumor involving his entire trachea. He was
eventually extubated and the patient and his family decided
on placement in hospice care.
2. Discussion
EOO is a rare condition, comprising approximately 1% of
all soft tissue sarcomas [1]. True EOO of the esophagus
h a so n l yb e e nr e p o r t e di no n ep a t i e n tb a c ki nt h ee a r l y
1980s [2]. In contrast to primary osteosarcoma, EOO
tends to present at an older age (median age 50.7 years)
[3]. More common anatomical sites for EOO include the
lower extremities and retroperitoneum. Similar to osseous
osteosarcoma, most patients with EOO will not have lymph
node involvement. Interestingly, this case involved extensive
lymph node involvement. Possible causes for EOO include
radiation and trauma, neither being present in this case [4].
Most EOOs are high grade. Microscopically EOOs con-
sist of neoplastic osteoid and bone, and frequently neoplastic
cartilage. EOOs will stain positively for vimentin and there
are now monoclonal antibodies to osteonectin and osteo-
calcin to help recognize skeletal and extraskeletal osteosar-
comas. The above case involved areas of eosinophilic stro-
mal hyaline-like material, interpreted by the pathologist as
osteoid.Thesamplestakenwerealsopositiveforosteonectin.
Thediﬀerentialdiagnosisofbone-andcartilage-formingsoft
tissue lesions can be long and sometimes diﬃcult to narrow.
Malignant lesions that can produce bone or cartilage include
synovial sarcoma, epithelioid sarcoma, malignant ﬁbrous
histiosarcoma, liposarcoma, malignant melanoma, as well as
others. Most of these neoplasms will have osteoid or bone
in only a small portion of the tumor in a well-diﬀerentiated
pattern. Oftentimes this is the only way to distinguish some
of the above diagnoses from EOO [5].
(a)
(b)
Figure 2:Pathologyslide.(a)Tumorcellsfromtheesophagealmass
shown to be negative for pankeratin, with presence of actin being
equivocal. (b)The submucosaof the esophagus contains mitotically
active spindle cells and pleomorphic spindle cells with eosinophilic
cytoplasm and focal areas containing eosinophilic stromal hyaline-
like material, likely osteoid.
Figure 3: Lobulated, calciﬁed esophageal mass at T4 level, as seen
on CT scan. The mass almost completely surrounds the trachea and
essentially obliterates the esophagus. Extensive calciﬁcation of a soft
tissue mass and its presumed metastases should make one consider
EOO as a possible diagnosis.Sarcoma 3
PatientspresentingwithlocalizedEOOhavetraditionally
been treated with surgical resection and chemotherapy.
Radiation has been used in the past with little success, and
is now used sparingly for palliation [4]. Patients are usually
treated with four cycles of doxorubicin-based chemotherapy.
A study of outcomes in 60 patients with EOO showed
only a 19% objective response rate to doxorubicin-based
chemotherapy. Ifosfamide is sometimes used in combination
with doxorubicin with reported response rates of 25%.
Cisplatin has also been studied in the treatment of EOO
with response rates of 13%. In patients treated with any of
the above chemotherapies, approximately 40–50% will have
progressive disease [6]. In the previously reported case of
EOO of the esophagus, the patient was diagnosed with EOO
after esophagogastrectomy with T-tube feeding jejunostomy.
The patient died shortly after postoperative discharge from
aspiration pneumonia.
The overall prognosis for patients with EOO remains
poor. Only about 1/3 of patients will survive for a long term.
Many patients will have local recurrence and most will die of
metastatic disease in 2-3 years [5]. Those patients presenting
withmetastaticdisease,asinthiscase,haveamediansurvival
of 8 months [6].
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